Journal of Clinical Epidemiology
Volume 53, Issue 3 , Pages 229-235 , March 2000

Vital epidemiologic clues in heart failure

  • W.B Kannel

      Affiliations

    • Framingham Heart Study, 5 Thurber St., Framingham, MA 01702 USA
    • Corresponding Author InformationCorresponding author. Dr. W. B. Kannel, Framingham Heart Study, 5 Thurber Street, Framingham, MA 01702. Reprints are not available

Received 15 December 1998 ,Revised 10 June 1999 ,Accepted 16 June 1999.

References 

  1. National Heart Lung and Blood Institute . Data fact sheet (Congestive Heart Failure in the United States: A New Epidemic). Bethesda, MD: NHLBI Information Center; 1996;
  2. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301–306
  3. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure (The Framingham Study). J Am Coll Cardiol. 1993;22A6a–13a:
  4. Kannel WB, Thom TJ. Incidence prevalence and mortality of cardiovascular diseases. In:  Schlant RC editors. The Heart. 8th ed. New York: McGraw-Hill; 1994;
  5. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on morbidity and mortality in patients with heart failure (Collaborative Group on ACE-Inhibitor Trials). JAMA. 1995;273:1450–1456
  6. Changes in mortality from heart failure—United States, 1980–1995. Morbid Mortal Weekly Rep 1998;47(30):633–7.
  7. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics. 1995;7(2):119–127
  8. American Heart Association. 1997 Heart and Stroke: Statistical Update. Dallas, TX.
  9. Graves EG, Gillum BS. 1994 Summary (National Hospital Discharge Survey: Advance Data). National Center for Health Statistics. 1996;278:1–12
  10. Ranofsky A. Inpatient utilization of short stay hospitalization by diagnosis. United States. 1971. National Center for Health Statistics. DHEW Pub No. (HRA) 75-1767; 1974.
  11. Brown AM, Cleland JGF. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 1998;19:1063–1069
  12. McMurray J, McDonough T, Morrison CE, Dargie HJ. Trends for hospitalization for heart failure in Scotland. 1980–1990. Eur Heart J. 1993;14:1158–1162
  13. Cleland JGF, Erdmann E, Ferrari R. Guidelines for the diagnosis of heart failure. Eur Heart J. 1995;16:741–751
  14. National Heart Lung and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Disease. NIH, Bethesda, MD; 1996.
  15. SOLVD Investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691
  16. Gandhi MM. Clinical epidemiology of coronary heart disease in the UK. Br J Hospital Med. 1997;58:23–27
  17. The CONSENSUS Trial Study Group . Effect of enalapril on mortality in severe congestive heart failure. Results of the co-operative North Scandinavian Enalapril Survival Study. New Engl J Med. 1987;316:1429–1435
  18. The Acute Infarction Rampiril Efficacy (AIRE) Study Investigators . Effect of Rampiril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:8321–8328
  19. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 1993;88(5):2277–2283
  20. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302
  21. Brophy TM. Epidemiology of congestive heart failure (Canadian data from 1970 to 1989). Can J Cardiol. 1992;8(5):495–498
  22. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562
  23. National High Blood Pressure Education Working Group . National High Blood Pressure Education Working Group on primary prevention of hypertension. Arch Intern Med. 1993;153:186–208
  24. Lackland DT, Kiel JE. Epidemiology of hypertension in African Americans. Semin Nephrol. 1996;16:63–70
  25. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72:S3–S9
  26. Kannel WB. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol. 1996;49:S3–S9
  27. Kannel WB, Wilson PWF. Comparison of risk profiles for cardiovascular events (implications for prevention). Adv Intern Med. 1997;42:39–66
  28. Gillum RF. Idiopathic cardiomyopathy on the United States, 1970–1982. Am Heart J. 1986;11:752–755
  29. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy. A population based study. Ann Intern Med. 1992;117(2):117–123
  30. Rakar S, Sinagra A, Di Lenarda A, Poletti A, Bussani R, Silvestri F, et al. Epidemiology of dilated cardiomyopathy. A postmortem study of 5252 necropsies. Eur Heart J. 1997;18:117–123
  31. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951–957
  32. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566
  33. US Department of Health and Human Services. National Heart Lung and Blood Institute. Report of the Task Force on Research on Heart Failure; 1994.
  34. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)). Lancet. 1994;344:1380–1389
  35. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 1986;34:124–130
  36. Cutler JA, Psaty BM, McMahon S, Furberg CD. Public health issues in hypertension control (what has been learned from clinical trials). In:  Laragh JH,  Brenner BH editor. Hypertension (Pathophysiology, Diagnosis and Management). New York: Raven Press Ltd; 1995;p. 253–270
  37. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure; a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27–34

PII: S0895-4356(99)00135-3

Journal of Clinical Epidemiology
Volume 53, Issue 3 , Pages 229-235 , March 2000

Article Tools

* Image Usage & Resolution